The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data

Table 7 Table of adverse events

	Neutropenia ^{a, b} between day 1 and day 28	Anemia ^{a, b} between day 1 and day 28	Diarrhea between day 1 and day 7	Vomiting ^c between day 1 and day 7	Acute drug vomiting
AQ dose category (mg/kg) ^d
<25	7.0% (5/71)	19.3% (79/410)	4.7% (11/232)	9.3% (24/258)	4.7% (10/214)
25 to <30	20.4% (33/162)	24.1% (190/787)	6.5% (56/857)	9.7% (81/838)	12.9% (80/622)
30 to <35	17.9% (21/117)	21.3% (132/621)	5.8% (55/955)	9.9% (92/933)	11.3% (55/486)
35 to <40	35.3% (30/85)	24.8% (96/387)	7.1% (49/693)	11.3% (74/656)	12.5% (54/433)
40 to <45	30.8% (8/26)	26.9% (58/216)	7.4% (43/580)	13.9% (76/546)	14.7% (62/423)
≥45	21.4% (6/28)	25.7% (35/136)	15.1% (76/504)	12.9% (63/490)	19.1% (33/173)
Age category
<1 y	30.0% (15/50)	49.6% (64/129)	18.4% (52/282)	6.6% (19/287)	21.4% (27/126)
1 to <5 y	17.3% (44/255)	28.0% (437/1,558)	7.4% (189/2,565)	8.7% (228/2,611)	13.9% (230/1,655)
5 to <12 y	13.3% (14/105)	12.4% (50/402)	3.2% (16/505)	15.8% (69/436)	8.9% (26/292)
≥12 y	38.0% (30/79)	8.3% (39/468)	7.0% (33/469)	24.3% (94/387)	4.0% (11/278)
Overall	21.1% (103/489)	23.1% (590/2,557)	7.6% (290/3,821)	11.0% (410/3,721)	12.5% (294/2,351)

^aPresented only for patients without neutropenia/anemia at baseline.
^bNeutropenia defined as ≤1,200 neutrophils/μl for <12 years and ≤1,500 neutrophils/μl for ≥12 years. Anemia defined as hemoglobin < 10 g/dl.
^cExcludes acute drug vomiting within an hour of treatment administration.
^dAfter adjusting for age category and formulation, AOR = 1.17 [95% CI: 0.95-1.46]; P = 0.144 for the risk of neutropenia for every 5 mg/kg increase in AQ dose.
^dAfter adjusting for age category and formulation, AOR = 1.16 [95% CI: 1.07-1.24]; P < 0.001 for the risk of diarrhea for every 5 mg/kg increase in AQ dose.
^dAfter adjusting for age category and formulation, AOR = 1.20 [95% CI: 1.11-1.29]; P < 0.001 for the risk of general vomiting for every 5 mg/kg increase in AQ dose.
^dAfter adjusting for age category and formulation, AOR = 1.23 [95% CI: 1.11-1.36]; P < 0.001 for the risk of acute vomiting for every 5 mg/kg increase in AQ dose.

ISSN: 1741-7015